Actively Recruiting

Age: 18Years +
All Genders
ID06988618

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to-Severe Prurigo Nodularis in Adults

Led by Galderma R&D · Updated on 2026-06-01

600

Participants Needed

51

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the real-world effectiveness of nemolizumab in adults with moderate-to-severe Prurigo nodularis (PN), a chronic skin condition. This observational study aims to assess outcomes reported by both investigators and patients over six months, focusing on how the treatment works in routine clinical practice. The study follows adults newly prescribed nemolizumab by their physicians. Participants will be observed for about 12 months while receiving treatment as part of their regular medical care. No extra visits, procedures, or lab tests beyond usual clinical practice are required. A sub-study in Germany and the UK will have some participants record their itch intensity and sleep disturbance daily for the first two weeks through remote data collection. Participants will have routine clinical visits determined by their doctors, with data collected during these visits. Researchers will assess outcomes such as the Investigator Global Assessment of chronic prurigo and patient-reported peak itch intensity at six months and up to 12 months. Sleep disturbance and prurigo activity will also be tracked. This approach allows long-term monitoring of treatment effects in a real-world setting without added study-related procedures.

CONDITIONS

Brief Title

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants newly prescribed nemolizumab for Prurigo nodularis by their treating physician
  • Adults aged 18 years or older
  • Participants who have signed the written informed consent form
Not Eligible

You will not qualify if you...

  • Contraindications for nemolizumab use according to local guidelines
  • Use of investigational drugs within 3 months before baseline
  • Previous treatment with nemolizumab
  • Inability to understand informed consent or complete study questionnaires due to mental, physical, or language barriers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

screening and enrollment visit

Monitoring

Duration - Approximately 12 months

Participants who undergo routine care with nemolizumab for moderate-to-severe Prurigo Nodularis are observed over approximately 12 months through physician assessments and patient-reported outcome measures.

Visits occur according to routine clinical practice without additional study visits

Long-term Monitoring

Duration - 15 days

Participants in a sub-study complete daily Peak Pruritus and Sleep Disturbance rating scales remotely for the first 15 days to capture detailed symptom data.

Daily remote data collection from Day -1 to Day 14

Trial Site Locations

Total: 51 locations

1

Galderma Investigational Site # 8893

Birmingham, Alabama, United States, 35244

Not Yet Recruiting

2

Galderma Investigational Site # 7077

Phoenix, Arizona, United States, 85006-2754

Not Yet Recruiting

3

Galderma Investigational Site # 7060

Phoenix, Arizona, United States, 85008-3884

Not Yet Recruiting

4

Galderma Investigational Site # 7067

Tucson, Arizona, United States, 85718

Not Yet Recruiting

5

Galderma Investigational Site # 7074

Corona, California, United States, 92882

Not Yet Recruiting

6

Galderma Investigational Site # 6836

Fountain Valley, California, United States, 92708-3701

Actively Recruiting

7

Galderma Investigational Site # 8224

Fremont, California, United States, 94538-1603

Not Yet Recruiting

8

Galderma Investigational Site # 7064

Santa Monica, California, United States, 90404-2216

Not Yet Recruiting

9

Galderma Investigational Site # 7061

Castle Rock, Colorado, United States, 80109-8034

Not Yet Recruiting

10

Galderma Investigational Site # 7059

Fairfield, Connecticut, United States, 06824

Not Yet Recruiting

11

Galderma Investigational Site # 7087

Coral Gables, Florida, United States, 33134

Not Yet Recruiting

12

Galderma Investigational Site # 7063

Cutler Bay, Florida, United States, 33157

Not Yet Recruiting

13

Galderma Investigational Site # 7078

Miami, Florida, United States, 33173

Not Yet Recruiting

14

Galderma Investigational Site # 7070

North Miami Beach, Florida, United States, 33162-4708

Not Yet Recruiting

15

Galderma Investigational Site # 7091

Tampa, Florida, United States, 33615-4537

Not Yet Recruiting

16

Galderma Investigational Site # 7058

Chicago, Illinois, United States, 60641

Not Yet Recruiting

17

Galderma Investigational Site # 8142

Indianapolis, Indiana, United States, 46250-2041

Not Yet Recruiting

18

Galderma Investigational Site # 8012

Glendale, Maryland, United States, 20769-9182

Not Yet Recruiting

19

Galderma Investigational Site # 7068

Rockville, Maryland, United States, 20850-6243

Not Yet Recruiting

20

Galderma Investigational Site # 7065

Brighton, Massachusetts, United States, 02135

Not Yet Recruiting

21

Galderma Investigational Site # 7066

Auburn Hills, Michigan, United States, 48326-3396

Not Yet Recruiting

22

Galderma Investigational Site # 7071

Caledonia, Michigan, United States, 49316-7478

Not Yet Recruiting

23

Galderma Investigational Site # 7072

Troy, Michigan, United States, 48084-5260

Not Yet Recruiting

24

Galderma Investigational Site # 7053

Waterford, Michigan, United States, 48328

Not Yet Recruiting

25

Galderma Investigational Site # 7057

Lee's Summit, Missouri, United States, 64064

Not Yet Recruiting

26

Galderma Investigational Site # 7076

St Louis, Missouri, United States, 63141-7068

Not Yet Recruiting

27

Galderma Investigational Site # 7055

Portsmouth, New Hampshire, United States, 03801-7156

Actively Recruiting

28

Galderma Investigational Site # 7080

Auburn, New York, United States, 13021

Not Yet Recruiting

29

Galderma Investigational Site # 7052

East Syracuse, New York, United States, 13057

Not Yet Recruiting

30

Galderma Investigational Site # 8282

Mount Kisco, New York, United States, 10549-3035

Not Yet Recruiting

31

Galderma Investigational Site # 7056

New York, New York, United States, 10012-1354

Not Yet Recruiting

32

Galderma Investigational Site # 7051

New York, New York, United States, 10023

Not Yet Recruiting

33

Galderma Investigational Site # 7081

Dayton, Ohio, United States, 45414-2799

Not Yet Recruiting

34

Galderma Investigational Site # 8559

Philadelphia, Pennsylvania, United States, 19103-4738

Not Yet Recruiting

35

Galderma Investigational Site # 8238

Dallas, Texas, United States, 75230-5808

Not Yet Recruiting

36

Galderma Investigational Site # 7062

Edinburg, Texas, United States, 78539-4660

Not Yet Recruiting

37

Galderma Investigational Site # 7088

Grapevine, Texas, United States, 76051

Not Yet Recruiting

38

Galderma Investigational Site # 7069

Sugar Land, Texas, United States, 77478-3842

Not Yet Recruiting

39

Galderma Investigational Site # 7079

Vienna, Virginia, United States, 22182

Not Yet Recruiting

40

Galderma Investigational Site # 6374

Karlsruhe, Baden-Wurttemberg, Germany, 76133

Not Yet Recruiting

41

Galderma Investigational Site # 6369

Erlangen, Bavaria, Germany, 91054

Not Yet Recruiting

42

Galderma Investigation Site # 6367

Rostock, Mecklenburg-Vorpommern, Germany, 18057

Actively Recruiting

43

Galderma Investigational Site # 5437

Kiel, Schleswig-Holstein, Germany, 24105

Not Yet Recruiting

44

Galderma Investigational Site # 6387

Ahaus, Germany, 48683

Not Yet Recruiting

45

Galderma Investigational Site # 6385

Berlin, Germany, 10117

Actively Recruiting

46

Galderma Investigational Tracker Site # 6172

Berlin, Germany, 12203

Actively Recruiting

47

Galderma Investigational Site # 6386

Bielefeld, Germany, 33647

Actively Recruiting

48

Galderma Investigational Site # 6370

Haslach, Germany, 77716

Not Yet Recruiting

49

Galderma Investigational Site # 6384

Koblenz, Germany, 56068

Actively Recruiting

50

Galderma Investigational Site # 6373

Mainz, Germany, 55128

Actively Recruiting

51

Galderma Investigational Site # 6371

Oberursel, Germany, 61440

Actively Recruiting

Loading map...

Research Team

G

Galderma Research and Development

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Study to Describe Dupilumab Long-term Treatment, Safety, and...

Prurigo Nodularis

Actively Recruiting

11 locations

Phase 1a/1b Study Evaluating Safety, Tolerability, Pharmacok...

Healthy Participants

Actively Recruiting

13 locations

A Multicenter Open-label Study to Investigate the Pharmacoki...

Prurigo Nodularis

Actively Recruiting

14 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here